Provalis Sells its Point-of-Care Dx Business to Bio-Rad for $3M | GenomeWeb
NEW YORK (GenomeWeb News) - Bio-Rad said today that it has purchased the medical diagnostics business of Provalis for around $3 million in cash.
 
Provalis’ diagnostics business, based in the UK, sells point-of-care diagnostic products for chronic disease management of diabetes and osteoporosis. The unit’s principal products are the in2it A1c and Glycosal diagnostic tests for diabetes.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.